MS in the Field and in the Clinic

June 5, 2018

This Tuesday morning session will discuss clinical and field applications of mass spectrometry, such as proteomic genotyping, detection of cancer tumors and metastases, tissue profiling, and therapeutic drug monitoring. It will be chaired by Alan Rockwood of Rockwood Scientific Consulting and will be held in Ballroom 6CF from 8:30 to 10:30 a.m.

This Tuesday morning session will discuss clinical and field applications of mass spectrometry, such as proteomic genotyping, detection of cancer tumors and metastases, tissue profiling, and therapeutic drug monitoring. It will be chaired by Alan Rockwood of Rockwood Scientific Consulting and will be held in Ballroom 6CF from 8:30 to 10:30 a.m.

This session’s first presentation will be given by Christopher Shuford of Laboratory Corporation of America and is titled “Proteomic Genotyping, Now at Your Fingertips.” His talk will discuss the development of a generic bottom-up proteomic assay for identifying the Apo1 genotype of a patient. The assay provides the ability to genotype using a proteomic workflow with noninvasive in-home blood collection devices.

The next talk will be presented by Cornelia Koy of Proteome Center Rostock, in Rostock, Germany. Her presentation, titled “Mass Spectrometry Guides Western Blot Screening for Presence of Metastases in Lymph Nodes from Breast Cancer Patients,” will describe how MS-guided Western blotting allows metastasis detection in lymph nodes due to tissue-dependent expression of ezrin truncations.

Rémi Longuespée of the University of Heidelberg, Heidelberg, Germany will then give a talk titled “Rapid Detection of 2-Hydroxyglutarate in Tumor Frozen Sections by MALDI-TOF Mass Spectrometry.” This presentation will describe the first MALDI-TOF-based test for the intraoperative diagnosis of isocitrate dehydrogenase mutation status, which is important in the classification of brain tumors.

The next presentation, titled “Comparison of High- and Low-Resolution MS Data for Direct Tissue Profiling on a Way from Laboratory to Clinic,” will be given by Igor Popov of the Moscow Institute of Physics and Technology. His talk will discuss how low-resolution spectra preserve distinctive features of brain tumor samples and can possibly be used in sample classification.

Xiaolei Xie of Thermo Fisher Scientific in San Jose, California, will then present “Integrating Inborn Errors of Metabolism and Hemoglobin Variant Clinical Research into a Single HRAM Mass Spectrometer Workflow.” This presentation will describe the development of a high-resolution, high-throughput workflow for quantifying amino acids and acylcarnitines, and identifying hemoglobin variants in dried blood spot samples.

This session’s final presentation, titled “Free Fraction Analysis for Therapeutic Drug Monitoring of Antiepileptic Drugs,” will be given by Emily Barrey of MilliporeSigma, Bellefonte, Pennsylvania. Her presentation will discuss a simple, easily automated solid-phase microextraction method for quantitating the free fraction of the drugs pregabalin, levetiracetam, lamotrigine, felbamate, carbamazepine, and clonazepam.